Rui-Ling Feng

Topology-enabled long-acting interleukin-2 for advanced low-dose interleukin-2 therapy of autoimmune diseases

The therapeutic efficacy of protein biologics is often hampered by their rapid in vivo degradation and off-target effects. Interleukin-2 (IL-2), a cytokine promising for treating autoimmune diseases via regulatory T cell (Treg) expansion, exemplifies this challenge due to its short half-life and pleiotropic activity. H...